Literature DB >> 21147946

Managing gout: how is it different in patients with chronic kidney disease?

Hossam El-Zawawy1, Brian F Mandell.   

Abstract

Many patients with gout have comorbidities, including hypertension and chronic kidney disease (CKD). The goals when treating gout are no different in these patients, but the choice and dosage of drugs may need to be modified.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21147946     DOI： 10.3949/ccjm.77a.09080

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  10 in total

1.  Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis.

Authors:  Kiyonori Ito; Yuichiro Ueda; Haruhisa Miyazawa; Yoshio Kaku; Keiji Hirai; Taro Hoshino; Aoi Nabata; Honami Mori; Izumi Yoshida; Susumu Ookawara; Kaoru Tabei
Journal:  CEN Case Rep       Date:  2014-02-15

2.  Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment.

Authors:  Ryoko Horikoshi; Tetsu Akimoto; Makoto Inoue; Yoshiyuki Morishita; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2013-01-05       Impact factor: 2.801

3.  Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease.

Authors:  Suman Wason; David Mount; Robert Faulkner
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

4.  Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010.

Authors:  Stephen P Juraschek; Lara C Kovell; Edgar R Miller; Allan C Gelber
Journal:  Semin Arthritis Rheum       Date:  2013-01-09       Impact factor: 5.532

5.  The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Authors:  Robert L Jackson; Barbara Hunt; Patricia A MacDonald
Journal:  BMC Geriatr       Date:  2012-03-21       Impact factor: 3.921

Review 6.  Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.

Authors:  Matthew J Roughley; John Belcher; Christian D Mallen; Edward Roddy
Journal:  Arthritis Res Ther       Date:  2015-04-01       Impact factor: 5.156

7.  Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.

Authors:  William B Smith; Jesse Hall; Jolene K Berg; Michal Kazimir; Amy Yamamoto; Susan Walker; Caroline A Lee; Zancong Shen; David M Wilson; Dongmei Zhou; Michael Gillen; Thomas C Marbury
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

8.  Incident gout and chronic Kidney Disease: healthcare utilization and survival.

Authors:  Dena H Jaffe; Alyssa B Klein; Arriel Benis; Natalia M Flores; Hagit Gabay; Robert Morlock; Dana Y Teltsch; Jonathan Chapnick; Yair Molad; Shmuel M Giveon; Becca Feldman; Maya Leventer-Roberts
Journal:  BMC Rheumatol       Date:  2019-03-19

9.  Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.

Authors:  Tsu-Chen Lin; Lie Yee Hung; Ying-Chun Chen; Wei-Cheng Lo; Chun Hung Lin; Ka-Wai Tam; Mei-Yi Wu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

10.  Febuxostat for hyperuricemia in patients with advanced chronic kidney disease.

Authors:  Tetsu Akimoto; Yoshiyuki Morishita; Chiharu Ito; Osamu Iimura; Sadao Tsunematsu; Yuko Watanabe; Eiji Kusano; Daisuke Nagata
Journal:  Drug Target Insights       Date:  2014-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.